


# FISCAL YEAR 2024 STEWARDSHIP REPORT



**Barrow**  
Neurological Foundation

## Discovering Tomorrow's Treatments Today



## OUR GRATITUDE


Your generous support has been a driving force behind the Ivy Brain Tumor Center's relentless pursuit of a cure for brain cancer. Together, we've set a new standard for innovation in brain tumor research, challenging the status quo and offering hope to patients and families who have long been underserved.

As a valued partner in this mission, you know the sobering reality: Survival rates for malignant brain tumors have remained stagnant for decades, with glioblastoma claiming nearly 10,000 American lives each year. But thanks to your commitment, we are advancing where others have stalled, developing lifesaving therapies faster than ever before.

Your contributions impact every clinical trial we launch, every patient we enroll, and every breakthrough we achieve. Your support allows us to expand the reach of our Phase 0 clinical trials program, bringing precision medicine to patients who've run out of options and proving brain cancer research can—and must—move at the speed of life.

This report highlights the tangible progress you've made possible. From innovative treatments to paradigm-shifting discoveries, we're turning challenges into opportunities and delivering the future of brain tumor care to patients today.

With gratitude,



**Dr. Nader Sanai**

Francis & Dionne Najafi Chair in Neurosurgical Oncology  
Director, Ivy Brain Tumor Center  
Barrow Neurological Institute





# YOUR GENEROUS SUPPORT

## Fueling Measurable Success in Brain Cancer Research

In just six years, we have screened more than 4,500 patients and enrolled over 500 in 16 Phase 0 clinical trials. Your generous gift has been instrumental in expanding our portfolio of groundbreaking early-phase clinical trials. These accelerated trials quickly identify drugs that show promise while eliminating those that do not. Focusing on precision medicine, we create personalized treatment plans based on each patient's unique tumor genetics, giving every patient the best chance at success without sacrificing precious time.

Your investment has advanced our understanding of brain cancer and identified potential new treatment options, enabling us to revolutionize the way we approach brain cancer research.

To date, one uniquely promising therapy has already advanced from our early-phase clinical trials into a worldwide Phase 3 clinical trial.

The Ivy Center identified the drug niraparib and accelerated it into a Phase 0/2 clinical trial. In this initial study, niraparib achieved brain tumor penetration in excess of any other drug in its class, nearly doubling the median overall survival of patients to 20.3 months.

“

In less than two years, from concept to completion, our team at the Ivy Center generated proof-of-concept data in partnership with GSK, and we are now working to deliver a potential new standard of care to MGMT-unmethylated glioblastoma patients.”

—Dr. Nader Sanai, director of the Ivy Brain Tumor Center

## FDA APPROVAL

### Phase 3 Clinical Trial Advances

Data from our Phase 0/2 clinical trial of niraparib provided compelling evidence supporting the drug's potential as a new treatment option for patients with newly diagnosed glioblastoma. Traditionally, advancing from a Phase 1 to a Phase 3 trial is a decades-long endeavor, but our streamlined approach shortened the timeline with record efficiency.

In May 2024, we announced the Gliofocus Study (Gliofocus.org), a global Phase 3 clinical trial, and, in partnership with GSK, dosed our first patient just five weeks later. The study will enroll 450 patients at more than 145 medical centers across 11 countries. We intend to take successful study results to the FDA as evidence that this drug can extend the lives of glioblastoma patients and should define the new standard of care. This study could transform prognoses for these patients worldwide.

Read the Press Release:



Scan here



## REAL LIVES, REAL IMPACT

Scientific discovery and innovation drive everything we do, but our patients always come first. A culture of hope fuels our team and provides strength to patients, caregivers, and families as they navigate the challenges of brain cancer. Every story we share is a testament to the courage of our patients and to your unwavering support, which makes their care and treatment possible. Your generosity has not only advanced groundbreaking research but also created hope and opportunity for those who need it most.

### MARCUS JONES FACING BRAIN CANCER AT AGE 25

After 12 days of severe headaches, 25-year-old Marcus Jones reluctantly decided to see a doctor. He attributed the debilitating pain to exhaustion from the Ironman 70.3 race he completed a couple of weeks earlier. However, doctors had a different explanation: a large mass in his brain, likely a tumor.

*"It was a 'this-doesn't-happen-to-me' moment," Marcus recalls.*

Marcus was diagnosed with a grade 4 astrocytoma brain tumor and immediately underwent a six-hour operation to remove it. Because of the molecular signature of his tumor, Marcus qualified for a clinical trial aimed at stopping the tumor cells' ability to survive.

Today, despite the deadly diagnosis, Marcus is back to training for Ironman races and living as a typical 25-year-old should. He's grateful for options outside the standard of care and hopes the clinical trial he's participating in will help others like him.



Read Marcus' Story:



Scan here



*"I've fit so much more life into the last year and a half than I did before my brain tumor," Marie says. "You start not taking your time for granted anymore, or your health and your body."*

### MARIE DONAHUE HOW A BRAIN TUMOR INSPIRED A LIFE OF ADVENTURE

What does life look like after a brain tumor diagnosis? For Marie Donahue, it's scuba diving in cenotes in Mexico, skiing the Swiss Alps, and backpacking through several countries, even though the meningioma brain tumor she was diagnosed with threatened her mobility. After a nine-hour surgery, Marie could not feel or move her right side, a deficit her neurosurgeons expected. With physical and occupational therapy and neuro-rehab, Marie worked her way back to good health, and now she's taking full advantage of it.



## CAROL STEVENS

### CLINICAL TRIALS, WHY I PARTICIPATE

A harsh reality of brain cancer is that tumors often return. Carol Stevens experienced this firsthand when her glioblastoma returned just six months after undergoing the standard treatment regimen of surgery, radiation, and chemotherapy.

She needed something new – a different approach to fight this relentless disease. Giving up, Carol says, isn't an option.

She found an Ivy Center clinical trial testing an experimental drug designed specifically for her tumor's genetic composition. She was hesitant at first, but when faced with a glioblastoma diagnosis, Carol knew she would need to take an alternative approach.

In the Phase 0 portion of the trial, Ivy researchers confirmed the drug crossed the blood-brain barrier, reached the tumor, and had the intended effect. Now, in the therapeutic phase of the trial, the drug is proving to be successful at keeping her tumor at bay.



*"The Ivy Center is constantly looking for new and better ways of dealing with these tumors, getting rid of them, and keeping them away for longer," Carol says. "It gives you strength knowing that there are options."*

Watch  
Video:



Scan here



Scan here

**Read More Stories:** These inspiring stories are possible because of your generosity. Together, we are bringing hope to patients like Marcus, Marie, and Carol and changing the future of brain cancer care.

## PARTNERING TO FIND A CURE

### Kramer Family Foundation

The Kramer family's support of the Ivy Brain Tumor Center stems from a deeply personal connection to glioblastoma. In 1998, beloved husband and father Jim Kramer was diagnosed with the devastating disease. Throughout his fight, Barrow provided Jim with exceptional care, and they saw firsthand its dedication to advancing treatment options.

Since then, the family has supported cutting-edge research at the Ivy Center that fast-tracks clinical trials for promising drugs and provides hope to patients facing a brain tumor diagnosis.

For the Kramers, it has been inspiring to see how recent progress in research has led to significantly improved patient longevity prospects. They hope their continued support will lead to a day when a glioblastoma diagnosis is no longer a death sentence.

*"Supporting the Ivy Center is an investment in hope and progress," says Tracey Kramer. "We are proud to know that our contributions have played a role in advancing these research efforts to help more patients and families."*

# TRANSFORMING BRAIN CANCER CARE

At the Ivy Brain Tumor Center, we don't just conduct research—we're rewriting the playbook for brain cancer treatment. As the only program in the world operating at our pace, we're redefining what's possible with swift, data-driven results.

## DRIVING INNOVATION

- **Accelerated Clinical Trials:** In days—not months or years—we identify therapies that work and eliminate those that don't, giving patients faster access to lifesaving options.
- **Personalized Medicine:** We use advanced genetic profiling to tailor experimental treatments to each patient's unique tumor, offering hope where standard care falls short.
- **Cutting-Edge Technology:** From breakthrough neurosurgical techniques to experimental drug therapies, our patients benefit from the latest advancements before they're available anywhere else worldwide.

## BUILDING IMPACTFUL PARTNERSHIPS

Collaboration fuels progress. With support from pharmaceutical and biotech partners, we can access and test the most promising therapies. Generous contributions from donors like you provide the resources needed to fund these partnerships and expand our reach.

## PUTTING PATIENTS FIRST

Every decision we make centers on improving patient outcomes. From providing compassionate care to offering clinical trial opportunities unavailable anywhere else, our mission is to save lives and create hope.

Your unwavering support empowers our team to stay at the forefront of innovation, attract top talent, and build the infrastructure needed to transform brain cancer care.

TOGETHER, WE'RE NOT JUST  
CHANGING LIVES—

**WE'RE CHANGING  
THE FUTURE**  
OF BRAIN CANCER TREATMENT.



## AMPLIFYING OUR MESSAGE

Raising awareness is vital to the Ivy Center's mission of transforming brain cancer care. Our Marketing and Communications team drives this effort, sharing patient stories, expert insights, and clinical breakthroughs to inspire action and expand our reach. Through digital campaigns, community engagement, and media partnerships, the Ivy Center is connecting with patients, caregivers, and advocates around the globe.

## TURNING ENGAGEMENT INTO ACTION

Your support has enabled us to build a global platform for hope, with millions engaging with our message last year.



**30+**

**Patient Stories Shared:** Offering hope and guidance to others on similar journeys.



**1,854**

**Earned Media Mentions:** Bringing attention to cutting-edge brain cancer research.



**570,000**

**Website Visits:** Providing a trusted resource for patients and families worldwide.



**45+**

**Countries Reached:** Expanding our mission to a truly global audience.



**5M**

**Social Media Engagements:** Inspiring a movement to accelerate change.



One standout initiative is the *Brain Tumor Talk* podcast, launched in May 2024. Featuring leading experts, courageous survivors, and compassionate caregivers, the podcast provides invaluable knowledge and hope to those affected by brain cancer. With a steadily growing audience, it exemplifies how storytelling can drive awareness and action, empowering patients to consider clinical trials and equipping caregivers with valuable insight.



## TOGETHER, WE'RE ADVANCING **THE FIGHT AGAINST BRAIN CANCER**

At the Ivy Brain Tumor Center, our multidisciplinary team is dedicated to providing expert care, preserving patients' quality of life, and advancing treatment options through groundbreaking clinical research. We are profoundly grateful for your continued support, which drives our mission to improve outcomes and transform brain tumor research and treatment for those affected by this disease.

As we expand therapeutic options for our patients, philanthropic support remains crucial. With the backing of thousands of generous contributors like you, we are seizing this pivotal moment to accelerate research for this historically underfunded disease. Your steadfast commitment fuels lifesaving innovations and brings hope to brain tumor patients and their families across the globe.

Thank you for being an essential part of this transformative work.

**As we look ahead, your continued partnership will allow us to accelerate this progress and bring hope to even more patients and families.**

## TOGETHER, WE CAN ACHIEVE **EXTRAORDINARY BREAKTHROUGHS.**

### BY THE NUMBERS



**1,300**

Brain tumor surgeries performed annually - the largest volume in the U.S.



**4,500**

Patients screened for clinical trials



**26**

New drugs analyzed for advancement to clinical trial



**500+**

Patients enrolled in early-phase trials



**16**

Clinical trials launched



**12+**

Countries represented by our trial patients

**Barrow**  
Neurological Foundation

Barrow Neurological Foundation  
2910 N. Third Ave., Ste. 450, Phoenix, AZ 85013  
**SupportBarrow.org**

**John Pennant**  
Senior Director of Philanthropy  
Ivy Brain Tumor Center  
Barrow Neurological Foundation  
[John.Pennant@IvyBrainTumorCenter.org](mailto:John.Pennant@IvyBrainTumorCenter.org)  
480-212-6353